However, the pooled results showed no statistically significant association between BIM deletion polymorphism and OS in univariate analysis, revealing that it could not be emerged as a genetic biomarker to predict OS in EGFR-mutated NSCLC patient with TKI therapy in Asian population. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.